PharmaPoint: Non-Small Cell Lung Cancer - Japan Drug Forecast and Market Analysis to 2022


#174350

186pages

GlobalData

$ 4995

In Stock


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

GlobalData forecasts that the NSCLC market will grow in the forecast period. This growth will be largely attributable to a rapidly aging population and increased incident cases of the disease, as well as the launch of new targeted therapies to treat previously underserved patient segments with high unmet need.

Scope

  • Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan NSCLC market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Japan.
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology and Histology 14
3.1.3 NSCLC Biomarkers 15
3.1.4 Quality of Life 16
3.2 Symptoms 17

4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Diagnosis 20
4.1.2 Clinical Staging 21
4.1.3 Screening and Early Detection 23
4.1.4 Localized Procedures and Therapies 24
4.1.5 Systemic Chemotherapy 25
4.1.6 Targeted Therapy 26
4.2 Japan 28
4.2.1 Diagnosis 28
4.2.2 Clinical Practice 29

5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 32
5.3 Product Profiles Major Brands, Chemotherapies 34
5.3.1 Alimta (pemetrexed disodium) 34
5.3.2 Abraxane (nab-paclitaxel) 38
5.4 Product Profiles Major Brands, Targeted Therapies 42
5.4.1 Iressa (gefitinib) 42
5.4.2 Tarceva (erlotinib hydrochloride) 47
5.4.3 Xalkori (crizotinib) 52
5.4.4 Avastin (bevacizumab) 56

6 Opportunity and Unmet Need 60
6.1 Overview 60
6.2 Improved Overall Survival and Less Toxicity 61
6.3 Treatments for Patients with Acquired TKI Resistance 62
6.4 Better Treatment Options for Squamous Patients 62
6.5 Preventing Relapse or Recurrence 63
6.6 More Efficacious Second-Line Therapies 63
6.7 Increased Availability of Mutation Testing 64
6.8 More Cost-Effective Therapies 65
6.9 Unmet Needs Gap Analysis 65

7 Pipeline Assessment 69
7.1 Overview 69
7.2 Promising Drugs in Clinical Development 69
7.2.1 onartuzumab (MetMab) 73
7.2.2 necitumumab (IMC-11F8) 79
7.2.3 ramucirumab (IMC-1121B) 84
7.2.4 ganetespib (STA-9090) 88
7.2.5 nintedanib (BIBF1120) 94
7.2.6 Gilotrif (afatinib) 98
7.2.7 dacomitinib (PF-00299804) 104
7.2.8 LDK378 109
7.2.9 Yervoy (ipilimumab) 114
7.2.10 nivolumab (BMS936558) 118
7.2.11 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 124
7.2.12 Halaven (eribulin mesylate) 128

8 Market Outlook 133
8.1 Japan 133
8.1.1 Forecast 133
8.1.2 Key Events 136
8.1.3 Drivers and Barriers 137

9 Appendix 140
9.1 Bibliography 140
9.2 Abbreviations 158
9.3 Methodology 162
9.4 Forecasting Methodology 162
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 162
9.4.2 Percent Drug-treated Patients 163
9.4.3 Drugs Included in Each Therapeutic Class 163
9.4.4 Launch and Patent Expiry Dates 164
9.4.5 General Pricing Assumptions 165
9.4.6 Individual Drug Assumptions 168
9.4.7 Generic Erosion 176
9.4.8 Pricing of Pipeline Agents 176
9.5 Physicians and Specialists Included in This Study 179
9.6 Survey of Prescribing Physicians 181
9.7 About the Authors 182
9.7.1 Authors 182
9.7.2 Epidemiologists 183
9.7.3 Global Head of Healthcare 184
9.8 About GlobalData 185
9.9 Disclaimer 185

Table 1: Symptoms of Disease NSCLC 18
Table 2: Treatment Guidelines for NSCLC 20
Table 3: Stage Definitions for NSCLC 22
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 28
Table 5: Leading Treatments for NSCLC 34
Table 6: Product Profile Alimta (pemetrexed disodium) 36
Table 7: Alimta SWOT Analysis, 2013 38
Table 8: Product Profile Abraxane (nab-paclitaxel) 39
Table 9: Abraxane SWOT Analysis, 2013 41
Table 10: Product Profile Iressa (gefitinib) 44
Table 11: Iressa SWOT Analysis, 2013 46
Table 12: Product Profile Tarceva (erlotinib hydrochloride) 48
Table 13: Tarceva SWOT Analysis, 2013 51
Table 14: Product Profile Xalkori (crizotinib) 53
Table 15: Xalkori SWOT Analysis, 2013 56
Table 16: Product Profile Avastin (bevacizumab) 57
Table 17: Avastin SWOT Analysis, 2013 59
Table 18: Overall Unmet Needs Current Level of Attainment 61
Table 19: Clinical Unmet Needs Gap Analysis, 2013 66
Table 20: Non-Small Cell Lung Cancer Phase I-II Pipeline, 2013 70
Table 21: NSCLC Phase III Pipeline, 2013 71
Table 22: NSCLC Advantages and Disadvantages of Therapeutic Classes 72
Table 23: Product Profile onartuzumab (MetMab) 74
Table 24: onartuzumab SWOT Analysis, 2013 79
Table 25: Product Profile necitumumab (IMC-11F8) 80
Table 26: necitumumab SWOT Analysis, 2013 84
Table 27: Product Profile ramucirumab (IMC-1121B) 85
Table 28: ramucirumab SWOT Analysis, 2013 88
Table 29: Product Profile ganetespib (STA-9090) 89
Table 30: ganetespib SWOT Analysis, 2013 94
Table 31: Product Profile nintedanib (BIBF-1120) 95
Table 32: nintedanib SWOT Analysis, 2013 98
Table 33: Product Profile Gilotrif (afatinib) 99
Table 34: Gilotrif SWOT Analysis, 2013 104
Table 35: Product Profile dacomitinib (PF-00299804) 105
Table 36: dacomitinib SWOT Analysis, 2013 108
Table 37: Product Profile LDK378 110
Table 38: LDK378 SWOT Analysis, 2013 114
Table 39: Product Profile Yervoy (ipilimumab) 115
Table 40: Yervoy SWOT Analysis, 2013 118
Table 41: Product Profile nivolumab (BMS936558) 119
Table 42: nivolumab SWOT Analysis, 2013 124
Table 43: Product Profile GSK1572932A (MAGE-A3 immunotherapy) 125
Table 44: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 128
Table 45: Product Profile Halaven (eribulin mesylate) 129
Table 46: Halaven SWOT Analysis, 2013 132
Table 47: Sales Forecasts ($m) for NSCLC in Japan, 2012-2022 134
Table 48: Key Events Impacting Sales for NSCLC in Japan, 2012-2022 136
Table 49: NSCLC Market in Japan Drivers and Barriers, 20122022 137
Table 50: Five Year Prevalence 163
Table 51: Key Launch Dates 164
Table 52: Key Patent Expiries 165
Table 53: Physicians Surveyed by Country 181
Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 20122022 72
Figure 2: Sales for NSCLC in Japan by Drug, 20122022 135